You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
In your paper, you mentioned that you used MS data for fine-tuning cell type annotation task, where the training data consist of normal patients and testing data consist of MS patients.
May I ask why you split the training and testing data in this way (you mentioned out of distribution data)? From my understanding, the gene expression profiles can be different for people with and without a disease. By only including people without a disease in the training data, would we be biasing the model in a certain way?
Thanks.
The text was updated successfully, but these errors were encountered:
In your paper, you mentioned that you used MS data for fine-tuning cell type annotation task, where the training data consist of normal patients and testing data consist of MS patients.
May I ask why you split the training and testing data in this way (you mentioned out of distribution data)? From my understanding, the gene expression profiles can be different for people with and without a disease. By only including people without a disease in the training data, would we be biasing the model in a certain way?
Thanks.
The text was updated successfully, but these errors were encountered: